THOROFARE, N.J.- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "ABI"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announced a contract valued at $864,000 for sales of its innovative Tri-Cholesterol "Check" tests in Australia, Singapore, the United Arab Emirates and Oman. The Company's products are being distributed in such regions by 36 Strategies General Trading LLC ("36S"), a Dubai-based procurement solutions company. Target customers in Australia, Singapore, the United Arab Emirates and Oman include military forces, medical associations, universities and large companies operating in the resources sector.

The Company's Tri-Cholesterol "Check" is a revolutionary finger-stick

blood sample technology and the only combined rapid test which provides

an estimate of both Total and High Density Lipoprotein ("HDL")

cholesterol levels; thereby providing an estimate of the subject's Low

Density Lipoprotein ("LDL") levels.

ABI's Tri-Cholesterol "Check" test carries a U.S. Food and Drug

Administration ("FDA") Over-the-Counter approval; three CE marks for

the European Economic Area; and a Health Canada approval.

Raymond F. Akers Jr., Ph.D, Executive Chairman of Akers Biosciences,

stated, "This order gives us confidence that this test could become a

very important and widely used test worldwide. There are an estimated

200 million people worldwide who have abnormal cholesterol levels. Our

self-administered point-of-care test for cholesterol is easy-to-use,

low cost, and revolutionary in point-of-care diagnostics. We are very

pleased with the sales results we have achieved in these regions in a

very short time through our distribution partner in the Middle East."

Revenue related to this order for Tri-Cholesterol "Check" tests (a

Rapid Enzymatic Assay product) was recognized in the accounts for the

six months ended June 30, 2014.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of

care screening and testing products designed to bring healthcare

information both rapidly and directly to the consumer or healthcare

provider. The Company has advanced the science of diagnostics while

responding to major shifts in healthcare through the development of

several proprietary platform technologies. The Company's

state-of-the-art rapid diagnostic assays can be performed virtually

anywhere in minutes when time is of the essence. The Company has

aligned with major healthcare companies and high volume medical

products distributors to maximize product offerings, and to be a major

worldwide competitor in diagnostics.

Additional information on the Company and its products can be found on

our website at www.akersbiosciences.com. Follow us on Twitter

@AkersBio.